TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of $0.12, $0.17 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $114.99 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of $444.4 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth